July 26, 2012-- Metabolix, Inc. (NASDAQ: MBLX), an innovation-driven bioscience company focused on delivering sustainable solutions for plastics, chemicals and energy, today announced that it has signed a letter of intent (“LOI”) with Antibióticos S.A. for production of Mirel TM biopolymer resin at its manufacturing facility in Leon, Spain.
Under the terms of the LOI, Metabolix will begin work immediately with Antibióticos to conduct a series of validation production runs to demonstrate fermentation and recovery of Mirel biopolymer resin on full production-scale equipment at Antibióticos. The companies plan to enter into a definitive contract manufacturing agreement for Mirel biopolymers based upon the validation production runs as well as completion of economic and engineering feasibility studies. Metabolix will own the Mirel biopolymer resin produced during the validation production runs.
“The agreement with Antibióticos represents a significant step forward in establishing a new supply chain for Mirel biopolymers to serve our customers worldwide and to continue product development in high value-added applications,” said Richard P. Eno, president and chief executive officer of Metabolix. “In addition, Antibióticos is located in the European Union near many of our targeted customers. We are impressed with the track record, technical expertise and facilities at Antibioticos, and believe their equipment is well-suited to the manufacturing process used to produce Mirel biopolymers at commercial scale.”
“This agreement brings together our experience and technical capacity with Metabolix’s technology and processes in a way that supports the values and vision of both companies,” said Daniele Pucci Di Benisichi, president of Antibióticos. “The first step of our work with Metabolix will be to validate their technology in our facility. Then, we’ll look ahead to creating a contract manufacturing agreement. Antibióticos follows a very demanding and selective approach for new projects and partners, and we’re particularly pleased to be working with Metabolix to deepen our work in sustainable technologies and diversify our business portfolio.”
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV